These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114 [TBL] [Abstract][Full Text] [Related]
50. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959 [TBL] [Abstract][Full Text] [Related]
51. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema. Solaiman KA; Diab MM; Abo-Elenin M Retina; 2010; 30(10):1638-45. PubMed ID: 20838357 [TBL] [Abstract][Full Text] [Related]
52. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME; Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322 [TBL] [Abstract][Full Text] [Related]
53. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. Hung KH; Lee SM; Lee SY; Lee FL; Yang CS J Ocul Pharmacol Ther; 2010 Feb; 26(1):85-90. PubMed ID: 20148661 [TBL] [Abstract][Full Text] [Related]
54. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461 [TBL] [Abstract][Full Text] [Related]
55. Intravitreal Brolucizumab for Chronic Central Serous Chorioretinopathy without Choroidal Neovascular Membrane - a Pilot Study. Ramamurthy SR; Behera UC; Narula R; Sadda SR; Narayanan R Semin Ophthalmol; 2024 Nov; 39(8):615-622. PubMed ID: 38270124 [TBL] [Abstract][Full Text] [Related]
56. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833 [TBL] [Abstract][Full Text] [Related]
57. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
58. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma. Kwon HJ; Kim M; Lee CS; Lee SC Am J Ophthalmol; 2012 Jul; 154(1):137-145.e1. PubMed ID: 22465363 [TBL] [Abstract][Full Text] [Related]
59. Treatment of persistent serous retinal detachment in Vogt-Koyanagi-Harada syndrome with intravitreal bevacizumab during the systemic steroid treatment. Reibaldi M; Russo A; Avitabile T; Uva MG; Franco L; Longo A; Toro MD; Cennamo G; Mariotti C; Neri P; Noci ND; Russo V Retina; 2014 Mar; 34(3):490-6. PubMed ID: 23903795 [TBL] [Abstract][Full Text] [Related]
60. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema. Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]